Amid recently broader vaccine manufacturing initiatives from the EU and European companies, the G7 summit in the mountains of Bavaria brought positive news to close gaps in vaccine manufacturing and medical products in the world.
According to a statement from the White House, G7 leaders officially launched the Global Infrastructure Partnership, PGII. The effort will aim to raise hundreds of billions of dollars to complete infrastructure projects across multiple sectors, including the medical and pharmaceutical manufacturing space.
The United States will seek to raise $200 billion for PGII over the next five years through grants, federal funding, and private sector investment. Along with other G7 countries, a total of $600 billion will be mobilized by 2027 for a wide range of global infrastructure investments.
One of the initial projects includes G7 members, the EU, multilateral organizations and US International Development Finance Corporations (DFCs) providing a $3.3 million technical assistance grant to the Institut Pasteur of Dakar (IPD) in Senegal.
The funds will be used to develop a flexible industrial-scale multi-vaccine manufacturing facility. The facility will have the potential to produce millions of doses of vaccines against Covid-19 and other diseases, with the potential to use both viral vector and mRNA technologies.
This comes at a time when Africa is increasingly becoming a focus for vaccine manufacturing.
On Thursday, BioNTech kicked off construction work on an mRNA manufacturing facility in Kigali, Rwanda. According to BioNTech, the facility – dubbed the African Modular mRNA Fabrication Facility – aims to have the first set of fabrication tools delivered to the site by the end of this year.
The Serum Institute in May also said it planned to establish its first manufacturing facility in Africa as part of a further step towards global expansion after successfully mass-producing and selling hundreds of million doses of Covid-19 vaccine from its India-based facilities. .
It also follows the EU’s launch of a new initiative for manufacturing vaccines and medicines in Latin America and the Caribbean to get medicines to the region faster.